How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results

How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
Apr 08 2026 10:19 UTC
#pfizer #oncology #ibrance #seagen #adcs #biosimilars #earnings #pipeline
rwatimes.io/articles/qz-how-pfizers-...

A US #appealscourt has reversed a 2023 decision that ordered #DaiichiSankyo to pay royalties on sales of its antibody-drug conjugate (#ADC) Enhertu to #Seagen, now part of #Pfizer.

buff.ly/AWM9US3

Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic... /PRNewswire/ -- Ottimo Pharma, a private biotech company, announces the appointment of world class industry veterans David Epstein as Chair & Chief Executive...

But that’s not all! Meanwhile, Ottimo Pharma exited stealth & joined the race, developing jankistomig, a PD1 x VEGFR2 bsAb (IND filing H2 2025). Former #Seagen CEO David Epstein returns to #oncology as Ottimo's Chair & CEO, after Seagen's acquisition by Pfizer $PFE
www.prnewswire.com/news-release...